VEGFA and renal cell carcinoma: The treatment of RCC employs FDA-approved agents such as mammalian target of rapamycin (mTOR), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and their corresponding receptors VEGFR and PDGFR [134,135].